Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer-Reference-Cited by-同舟云学术

Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer

Published:2010-01-05 Issue:3 Volume:53 Page:1086-1097
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Sutherlin Daniel P.¹,Sampath Deepak¹,Berry Megan¹,Castanedo Georgette¹,Chang Zhigang¹,Chuckowree Irina²,Dotson Jenna¹,Folkes Adrian²,Friedman Lori¹,Goldsmith Richard¹,Heffron Tim¹,Lee Leslie¹,Lesnick John¹,Lewis Cristina¹,Mathieu Simon¹,Nonomiya Jim¹,Olivero Alan¹,Pang Jodie¹,Prior Wei Wei¹,Salphati Laurent¹,Sideris Steve¹,Tian Qingping¹,Tsui Vickie¹,Wan Nan Chi²,Wang Shumei¹,Wiesmann Christian¹,Wong Susan¹,Zhu Bing-Yan¹

Affiliation:

1. Genentech, Inc., 1 DNA Way, South San Francisco, California 94080

2. Piramed Pharma, 957 Buckingham Avenue, Slough, Berks SL1 4NL, United Kingdom

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm901284w

Reference19 articles.

1. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

2. The Phosphoinositide 3-Kinase Pathway